

Carlos Taxonera

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/1996231/carlos-taxonera-publications-by-year.pdf>

Version: 2024-04-09

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

| | | | |
|--------------------|-------------------------|----------------|-----------------|
| 127 papers | 3,188 citations | 31 h-index | 52 g-index |
| 142 ext. papers | 3,868 ext. citations | 3.3 avg, IF | 4.87 L-index |

| # | Paper | IF | Citations |
|-----|---|------|-----------|
| 127 | Preferences and satisfaction of IBD patients after switching from adalimumab 40 mg weekly to 80 mg every other week given as a single injection: the ADASCAL study.. <i>Therapeutic Advances in Gastroenterology</i> , 2021 , 14, 17562848211056157 | 4.7 | |
| 126 | ECCO Guidelines on the Prevention, Diagnosis, and Management of Infections in Inflammatory Bowel Disease. <i>Journal of Crohnts and Colitis</i> , 2021 , 15, 879-913 | 1.5 | 22 |
| 125 | Can COVID-19 Trigger De Novo Inflammatory Bowel Disease?. <i>Gastroenterology</i> , 2021 , 160, 1029-1030 | 13.3 | 7 |
| 124 | What Is the Incidence of COVID-19 in Patients With IBD in Western Countries?. <i>Gastroenterology</i> , 2021 , 160, 1901-1902 | 13.3 | 8 |
| 123 | Recommendations of the Spanish Working Group on Crohn's Disease and Ulcerative Colitis (GETECCU) on screening and treatment of tuberculosis infection in patients with inflammatory bowel disease. <i>Gastroenterologā Y Hepatologā</i> , 2021 , 44, 51-66 | 0.9 | 1 |
| 122 | Tofacitinib in Ulcerative Colitis: Real-world Evidence From the ENEIDA Registry. <i>Journal of Crohnts and Colitis</i> , 2021 , 15, 35-42 | 1.5 | 13 |
| 121 | Innovation in IBD Care During the COVID-19 Pandemic: Results of a Cross-Sectional Survey on Patient-Reported Experience Measures. <i>Inflammatory Bowel Diseases</i> , 2021 , 27, 864-869 | 4.5 | 11 |
| 120 | ABP 501 (adalimumab-atto) in the treatment of inflammatory bowel disease: an example of evidence-based extrapolation. <i>Revista Espanola De Enfermedades Digestivas</i> , 2021 , 113, 737-738 | 0.9 | |
| 119 | Cost-effectiveness analysis of using innovative therapies for the management of moderate-to-severe ulcerative colitis in Spain. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2021 , 1-11 | 2.2 | 1 |
| 118 | Real-World Effectiveness and Safety of Tofacitinib in Patients With Ulcerative Colitis: Systematic Review With Meta-Analysis. <i>Inflammatory Bowel Diseases</i> , 2021 , | 4.5 | 15 |
| 117 | Recommendations for the detection of latent tuberculosis infection in patients with immune-mediated inflammatory diseases candidates for anti-TNF therapy may not be applicable in all settings. <i>Rheumatology International</i> , 2021 , 1 | 3.6 | |
| 116 | Risk of immunomediated adverse events and loss of response to infliximab in elderly patients with inflammatory bowel disease. A cohort study of the ENEIDA registry. <i>Journal of Crohnts and Colitis</i> , 2021 , | 1.5 | 1 |
| 115 | Effectiveness and Safety of the Sequential Use of a Second and Third Anti-TNF Agent in Patients With Inflammatory Bowel Disease: Results From the Eneida Registry. <i>Inflammatory Bowel Diseases</i> , 2020 , 26, 606-616 | 4.5 | 19 |
| 114 | Letter: immunotherapy for IBD patients in a SARS-CoV-2 endemic area-authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2020 , 52, 900-901 | 6.1 | 1 |
| 113 | 2019 novel coronavirus disease (COVID-19) in patients with inflammatory bowel diseases. <i>Alimentary Pharmacology and Therapeutics</i> , 2020 , 52, 276-283 | 6.1 | 117 |
| 112 | Changes in the requirement for early surgery in inflammatory bowel disease in the era of biological agents. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2020 , 35, 2080-2087 | 4 | 9 |
| 111 | Usefulness of monitoring antitumor necrosis factor serum levels during the induction phase in patients with Crohn's disease. <i>European Journal of Gastroenterology and Hepatology</i> , 2020 , 32, 588-596 | 2.2 | 2 |

| | | | |
|-----|---|-----|----|
| 110 | Tacrolimus induces short-term but not long-term clinical response in inflammatory bowel disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2020 , 51, 870-879 | 6.1 | 4 |
| 109 | Letter: intestinal inflammation, COVID-19 and gastrointestinal ACE2-exploring RAS inhibitors. Authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2020 , 52, 571-572 | 6.1 | 3 |
| 108 | OP29 Tofacitinib in ulcerative colitis: Real-world evidence from Eneida Registry. <i>Journal of Crohns and Colitis</i> , 2020 , 14, S026-S028 | 1.5 | 1 |
| 107 | Switching to a Second Thiopurine in Adult and Elderly Patients With Inflammatory Bowel Disease: A Nationwide Study From the ENEIDA Registry. <i>Journal of Crohns and Colitis</i> , 2020 , 14, 1290-1298 | 1.5 | 4 |
| 106 | Letter: SARS-CoV-2 induced gastrointestinal inflammation-authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2020 , 52, 1750-1751 | 6.1 | 2 |
| 105 | Interstitial and Granulomatous Lung Disease in Inflammatory Bowel Disease Patients. <i>Journal of Crohns and Colitis</i> , 2020 , 14, 480-489 | 1.5 | 9 |
| 104 | Antitumor Necrosis Factor Agents to Treat Endoscopic Postoperative Recurrence of Crohn's Disease: A Nationwide Study With Propensity-Matched Score Analysis. <i>Clinical and Translational Gastroenterology</i> , 2020 , 11, e00218 | 4.2 | 0 |
| 103 | Real-life experience with 4 years of golimumab persistence in ulcerative colitis patients. <i>Scientific Reports</i> , 2020 , 10, 17774 | 4.9 | 3 |
| 102 | P584 Use of mycophenolate mofetil in inflammatory bowel disease: results from the ENEIDA registry. <i>Journal of Crohns and Colitis</i> , 2020 , 14, S489-S490 | 1.5 | |
| 101 | Recurrent granulomatous cheilitis associated with Crohn's disease successfully treated with ustekinumab: case report and literature review. <i>Therapeutic Advances in Gastroenterology</i> , 2020 , 13, 1756284820934327 | 4.7 | 5 |
| 100 | Letter: severe COVID-19 infection and biologic therapies-a cohort study of 7808 patients in France. Authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2020 , 52, 1249-1250 | 6.1 | |
| 99 | Increased risk of thiopurine-related adverse events in elderly patients with IBD. <i>Alimentary Pharmacology and Therapeutics</i> , 2019 , 50, 780-788 | 6.1 | 20 |
| 98 | Functional rare variants influence the clinical response to anti-TNF therapy in Crohn's disease. <i>Therapeutic Advances in Gastroenterology</i> , 2019 , 12, 1756284819867848 | 4.7 | |
| 97 | DOP44 Efficacy and safety of tacrolimus in ulcerative colitis: a nationwide, multi-centre study from GETECCU. <i>Journal of Crohns and Colitis</i> , 2019 , 13, S052-S053 | 1.5 | |
| 96 | P443 Clinical features, therapeutic requirements, and evolution of patients with Crohn's disease and upper digestive tract involvement (CROHNEX study). <i>Journal of Crohns and Colitis</i> , 2019 , 13, S332-S333 | 1.5 | |
| 95 | Endoscopic follow-up and therapeutic attitude after ileocolonic resection in a nationwide Spanish cohort of Crohn's disease patients: the Practicrohn study. <i>Expert Review of Gastroenterology and Hepatology</i> , 2019 , 13, 807-813 | 4.2 | 2 |
| 94 | Real-world short-term effectiveness of ustekinumab in 305 patients with Crohn's disease: results from the ENEIDA registry. <i>Alimentary Pharmacology and Therapeutics</i> , 2019 , 50, 278-288 | 6.1 | 32 |
| 93 | Clinical Characteristics, Associated Malignancies and Management of Primary Sclerosing Cholangitis in Inflammatory Bowel Disease Patients: A Multicentre Retrospective Cohort Study. <i>Journal of Crohns and Colitis</i> , 2019 , 13, 1492-1500 | 1.5 | 24 |

| | | | |
|----|---|-----|----|
| 92 | P559 Real-life experience with long-term maintenance of golimumab in ulcerative colitis patients. <i>Journal of Crohns and Colitis</i> , 2019 , 13, S393-S394 | 1.5 | |
| 91 | Adalimumab or Infliximab for the Prevention of Early Postoperative Recurrence of Crohn Disease: Results From the ENEIDA Registry. <i>Inflammatory Bowel Diseases</i> , 2019 , 25, 1862-1870 | 4.5 | 14 |
| 90 | P223 Efficacy and safety of tacrolimus in Crohn's disease: a nationwide, multi-centric study from GETECCU. <i>Journal of Crohns and Colitis</i> , 2019 , 13, S207-S208 | 1.5 | |
| 89 | P424 Is the switch to a second thiopurine a safe strategy in elderly patients with inflammatory bowel disease? A multi-centre cohort study of the ENEIDA registry. <i>Journal of Crohns and Colitis</i> , 2019 , 13, S321-S322 | 1.5 | 1 |
| 88 | Early dose optimization of golimumab induces late response and long-term clinical benefit in moderately to severely active ulcerative colitis. <i>Current Medical Research and Opinion</i> , 2019 , 35, 1297-1304 | 3.5 | 6 |
| 87 | Quality of life during one year of postoperative prophylactic drug therapy after intestinal resection in Crohn's patients: Results of the APPRECIA trial. <i>Digestive and Liver Disease</i> , 2019 , 51, 529-535 | 3.3 | 2 |
| 86 | Management and outcomes of patients with Crohn's disease with first vs multiple surgeries: results from the PRACTICROHN study. <i>Gastroenterology Report</i> , 2019 , 7, 411-418 | 3.3 | 1 |
| 85 | P437 Risk of immunomediated adverse events or secondary loss of response to infliximab in elderly patients with inflammatory bowel disease: a cohort study of the ENEIDA registry. <i>Journal of Crohns and Colitis</i> , 2019 , 13, S328-S329 | 1.5 | |
| 84 | Differences in the need for adalimumab dose optimization between Crohn's disease and ulcerative colitis. <i>Revista Espanola De Enfermedades Digestivas</i> , 2019 , 111, 846-851 | 0.9 | 3 |
| 83 | Anti-tumour necrosis factor discontinuation in inflammatory bowel disease patients in remission: study protocol of a prospective, multicentre, randomized clinical trial.. <i>Therapeutic Advances in Gastroenterology</i> , 2019 , 12, 1756284819874202 | 4.7 | 0 |
| 82 | Correlation Between Anti-TNF Serum Levels and Endoscopic Inflammation in Inflammatory Bowel Disease Patients. <i>Digestive Diseases and Sciences</i> , 2019 , 64, 846-854 | 4 | 15 |
| 81 | Differences between childhood- and adulthood-onset inflammatory bowel disease: the CAROUSEL study from GETECCU. <i>Alimentary Pharmacology and Therapeutics</i> , 2019 , 49, 419-428 | 6.1 | 18 |
| 80 | Long-Term Safety of In Utero Exposure to Anti-TNF Drugs for the Treatment of Inflammatory Bowel Disease: Results from the Multicenter European TEDDY Study. <i>American Journal of Gastroenterology</i> , 2018 , 113, 396-403 | 0.7 | 92 |
| 79 | Addition of Granulocyte/Monocyte Apheresis to Oral Prednisone for Steroid-dependent Ulcerative Colitis: A Randomized Multicentre Clinical Trial. <i>Journal of Crohns and Colitis</i> , 2018 , 12, 687-694 | 1.5 | 7 |
| 78 | Adalimumab for Induction of Histological Remission in Moderately to Severely Active Ulcerative Colitis. <i>Digestive Diseases and Sciences</i> , 2018 , 63, 731-737 | 4 | 11 |
| 77 | Eosinophilic colitis: Case series and literature review. <i>Pathology Research and Practice</i> , 2018 , 214, 100-104 | 3.4 | 18 |
| 76 | Prevention and treatment of tuberculosis infection in candidates for biologic therapy: A multidisciplinary consensus statement adapted to the dermatology patient. <i>Actas Dermo-sifiliograficas</i> , 2018 , 109, 584-601 | 0.5 | 2 |
| 75 | Reliability evaluation of four different assays for therapeutic drug monitoring of infliximab levels. <i>Therapeutic Advances in Gastroenterology</i> , 2018 , 11, 1756284818783613 | 4.7 | 9 |

| | | | |
|----|--|-----|-----|
| 74 | Serial Tuberculin Skin Tests Improve the Detection of Latent Tuberculosis Infection in Patients With Inflammatory Bowel Disease. <i>Journal of Crohns and Colitis</i> , 2018 , 12, 1270-1279 | 1.5 | 12 |
| 73 | Short and long-term effectiveness and safety of vedolizumab in inflammatory bowel disease: results from the ENEIDA registry. <i>Alimentary Pharmacology and Therapeutics</i> , 2018 , 48, 839-851 | 6.1 | 53 |
| 72 | Adalimumab vs Azathioprine in the Prevention of Postoperative Crohn's Disease Recurrence. A GETECCU Randomised Trial. <i>Journal of Crohns and Colitis</i> , 2017 , 11, 1293-1301 | 1.5 | 43 |
| 71 | Early Tuberculin Skin Test for the Diagnosis of Latent Tuberculosis Infection in Patients with Inflammatory Bowel Disease. <i>Journal of Crohns and Colitis</i> , 2017 , 11, 792-800 | 1.5 | 13 |
| 70 | Adalimumab Maintenance Treatment in Ulcerative Colitis: Outcomes by Prior Anti-TNF Use and Efficacy of Dose Escalation. <i>Digestive Diseases and Sciences</i> , 2017 , 62, 481-490 | 4 | 31 |
| 69 | Evolution After Anti-TNF Discontinuation in Patients With Inflammatory Bowel Disease: A Multicenter Long-Term Follow-Up Study. <i>American Journal of Gastroenterology</i> , 2017 , 112, 120-131 | 0.7 | 66 |
| 68 | DOP063 Serial tuberculin skin test improves the detection of latent tuberculosis infection in inflammatory bowel disease patients. <i>Journal of Crohns and Colitis</i> , 2017 , 11, S63-S63 | 1.5 | |
| 67 | Incidence and Management of Recurrence in Patients with Crohn's Disease Who Have Undergone Intestinal Resection: The Practicrohn Study. <i>Inflammatory Bowel Diseases</i> , 2017 , 23, 1840-1846 | 4.5 | 16 |
| 66 | Clinical Outcomes of Golimumab as First, Second or Third Anti-TNF Agent in Patients with Moderate-to-Severe Ulcerative Colitis. <i>Inflammatory Bowel Diseases</i> , 2017 , 23, 1394-1402 | 4.5 | 47 |
| 65 | Treatment persistence during therapeutic sequences with adalimumab and infliximab in the treatment of Crohn's disease. <i>Revista Espanola De Enfermedades Digestivas</i> , 2017 , 109, 690-693 | 0.9 | 1 |
| 64 | Ustekinumab for the Treatment of Refractory Crohn's Disease: The Spanish Experience in a Large Multicentre Open-label Cohort. <i>Inflammatory Bowel Diseases</i> , 2016 , 22, 1662-9 | 4.5 | 113 |
| 63 | Diagnostic Performance of the Simple Clinical Colitis Activity Index Self-Administered Online at Home by Patients With Ulcerative Colitis: CRONICA-UC Study. <i>American Journal of Gastroenterology</i> , 2016 , 111, 261-8 | 0.7 | 30 |
| 62 | Effectiveness of anti-TNF drugs in patients with Crohn's disease who do not achieve remission with their first anti-TNF agent. <i>Digestive and Liver Disease</i> , 2016 , 48, 613-9 | 3.3 | 9 |
| 61 | Outcomes of Medical and Surgical Therapy for Entero-urinary Fistulas in Crohn's Disease. <i>Journal of Crohns and Colitis</i> , 2016 , 10, 657-62 | 1.5 | 17 |
| 60 | Physician Perspectives on Unresolved Issues in the Management of Ulcerative Colitis: The UC Horizons Project. <i>Inflammatory Bowel Diseases</i> , 2016 , 22, 583-98 | 4.5 | 1 |
| 59 | Standardization of the homogeneous mobility shift assay protocol for evaluation of anti-infliximab antibodies. Application of the method to Crohn's disease patients treated with infliximab. <i>Biochemical Pharmacology</i> , 2016 , 122, 33-41 | 6 | 9 |
| 58 | Incidence, management, and course of cancer in patients with inflammatory bowel disease. <i>Journal of Crohns and Colitis</i> , 2015 , 9, 326-33 | 1.5 | 23 |
| 57 | Infliximab Dose Escalation as an Effective Strategy for Managing Secondary Loss of Response in Ulcerative Colitis. <i>Digestive Diseases and Sciences</i> , 2015 , 60, 3075-84 | 4 | 21 |

| | | | |
|----|--|------|-----|
| 56 | Response to Infliximab in Crohn's Disease: Genetic Analysis Supporting Expression Profile. <i>Mediators of Inflammation</i> , 2015 , 2015, 318207 | 4.3 | 14 |
| 55 | Recomendaciones del Grupo Español de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa (GETECCU) sobre el cribado y tratamiento de la tuberculosis latente en pacientes con enfermedad inflamatoria intestinal. <i>Enfermedad Inflamatoria Intestinal Al Día</i> , 2015 , 14, 109-119 | | 3 |
| 54 | Role of TNFRSF1B polymorphisms in the response of Crohn's disease patients to infliximab. <i>Human Immunology</i> , 2014 , 75, 71-5 | 2.3 | 33 |
| 53 | Need for infliximab dose intensification in Crohn's disease and ulcerative colitis. <i>World Journal of Gastroenterology</i> , 2014 , 20, 9170-7 | 5.6 | 19 |
| 52 | How frequently do tuberculosis screening tests convert in inflammatory bowel disease patients on anti-tumour necrosis factor-alpha? A pilot study. <i>Digestive and Liver Disease</i> , 2013 , 45, 733-7 | 3.3 | 11 |
| 51 | Health care costs of complex perianal fistula in Crohn's disease. <i>Digestive Diseases and Sciences</i> , 2013 , 58, 3400-6 | 4 | 24 |
| 50 | Letter: Recommendations for the management of latent tuberculosis infection in IBD patients may not be applicable in all settings. <i>Alimentary Pharmacology and Therapeutics</i> , 2013 , 37, 365-6 | 6.1 | 2 |
| 49 | Safety of thiopurines and anti-TNF- α drugs during pregnancy in patients with inflammatory bowel disease. <i>American Journal of Gastroenterology</i> , 2013 , 108, 433-40 | 0.7 | 157 |
| 48 | Early azathioprine therapy is no more effective than placebo for newly diagnosed Crohn's disease. <i>Gastroenterology</i> , 2013 , 145, 766-74.e1 | 13.3 | 180 |
| 47 | Genital fistulas in female Crohn's disease patients.: clinical characteristics and response to therapy. <i>Journal of Crohns and Colitis</i> , 2012 , 6, 276-80 | 1.5 | 27 |
| 46 | Induction of psoriasis with anti-TNF agents in patients with inflammatory bowel disease: a report of 21 cases. <i>Journal of Crohns and Colitis</i> , 2012 , 6, 518-23 | 1.5 | 65 |
| 45 | Adalimumab reversed a severe lymphopenia in a patient with Crohn's disease. <i>Journal of Crohns and Colitis</i> , 2012 , 6, 488-91 | 1.5 | 2 |
| 44 | Using of magnetic resonance enterography in the management of Crohn's disease of the small intestine: first year of experience. <i>Revista Espanola De Enfermedades Digestivas</i> , 2012 , 104, 578-83 | 0.9 | 16 |
| 43 | Evaluation of liver fibrosis by transient elastography (Fibroscan \square) in patients with inflammatory bowel disease treated with methotrexate: a multicentric trial. <i>Scandinavian Journal of Gastroenterology</i> , 2012 , 47, 575-9 | 2.4 | 38 |
| 42 | Methotrexate in inflammatory bowel disease: a multicenter retrospective study focused on long-term efficacy and safety. The Madrid experience. <i>European Journal of Gastroenterology and Hepatology</i> , 2012 , 24, 1086-91 | 2.2 | 19 |
| 41 | Mucosal healing for predicting clinical outcome in patients with ulcerative colitis using thiopurines in monotherapy. <i>European Journal of Internal Medicine</i> , 2011 , 22, 621-5 | 3.9 | 26 |
| 40 | Analysis of the influence of two CD24 genetic variants in Crohn's disease and ulcerative colitis. <i>Human Immunology</i> , 2011 , 72, 969-72 | 2.3 | 16 |
| 39 | Adalimumab induction and maintenance therapy for patients with ulcerative colitis previously treated with infliximab. <i>Alimentary Pharmacology and Therapeutics</i> , 2011 , 33, 340-8 | 6.1 | 76 |

| | | | |
|----|--|------|-----|
| 38 | Differential association of two PTPN22 coding variants with Crohn's disease and ulcerative colitis. <i>Inflammatory Bowel Diseases</i> , 2011 , 17, 2287-94 | 4.5 | 61 |
| 37 | High prevalence of viable <i>Mycobacterium avium</i> subspecies paratuberculosis in Crohn's disease. <i>World Journal of Gastroenterology</i> , 2010 , 16, 4558-63 | 5.6 | 37 |
| 36 | Outcomes of pregnancies fathered by inflammatory bowel disease patients exposed to thiopurines. <i>American Journal of Gastroenterology</i> , 2010 , 105, 2003-8 | 0.7 | 56 |
| 35 | Study of chromosomal region 5p13.1 in Crohn's disease, ulcerative colitis, and rheumatoid arthritis. <i>Human Immunology</i> , 2010 , 71, 826-8 | 2.3 | 8 |
| 34 | Non-invasive evaluation of the fibrosis stage in chronic hepatitis C: a comparative analysis of nine scoring methods. <i>Scandinavian Journal of Gastroenterology</i> , 2010 , 45, 51-9 | 2.4 | 3 |
| 33 | Emerging treatments for complex perianal fistula in Crohn's disease. <i>World Journal of Gastroenterology</i> , 2009 , 15, 4263-72 | 5.6 | 75 |
| 32 | Novel association of the interleukin 2-interleukin 21 region with inflammatory bowel disease. <i>American Journal of Gastroenterology</i> , 2009 , 104, 1968-75 | 0.7 | 44 |
| 31 | Fecal calprotectin and lactoferrin for the prediction of inflammatory bowel disease relapse. <i>Inflammatory Bowel Diseases</i> , 2009 , 15, 1190-8 | 4.5 | 222 |
| 30 | Role of ATG16L1 Thr300Ala polymorphism in inflammatory bowel disease: a Study in the Spanish population and a meta-analysis. <i>Inflammatory Bowel Diseases</i> , 2009 , 15, 1697-704 | 4.5 | 19 |
| 29 | Specific association of a CLEC16A/KIAA0350 polymorphism with NOD2/CARD15(-) Crohn's disease patients. <i>European Journal of Human Genetics</i> , 2009 , 17, 1304-8 | 5.3 | 42 |
| 28 | Effect of BSN-MST1 locus on inflammatory bowel disease and multiple sclerosis susceptibility. <i>Genes and Immunity</i> , 2009 , 10, 631-5 | 4.4 | 16 |
| 27 | Analysis of a non-synonymous single nucleotide polymorphism of the human diamine oxidase gene (ref. SNP ID: rs1049793) in patients with Crohn's disease. <i>Scandinavian Journal of Gastroenterology</i> , 2009 , 44, 1207-12 | 2.4 | 2 |
| 26 | Infliximab maintenance therapy is associated with decreases in direct resource use in patients with luminal or fistulizing Crohn's disease. <i>Journal of Clinical Gastroenterology</i> , 2009 , 43, 950-6 | 3 | 18 |
| 25 | Acute pancreatitis in inflammatory bowel disease, with special reference to azathioprine-induced pancreatitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2008 , 28, 623-8 | 6.1 | 95 |
| 24 | Open-label infliximab therapy in Crohn's disease: a long-term multicenter study of efficacy, safety and predictors of response. <i>Gastroenterología Y Hepatología</i> , 2008 , 31, 421-6 | 0.9 | 21 |
| 23 | Interaction of CYP2C8 and CYP2C9 genotypes modifies the risk for nonsteroidal anti-inflammatory drugs-related acute gastrointestinal bleeding. <i>Pharmacogenetics and Genomics</i> , 2008 , 18, 37-43 | 1.9 | 57 |
| 22 | IL23R and IL12B polymorphisms in Spanish IBD patients: no evidence of interaction. <i>Inflammatory Bowel Diseases</i> , 2008 , 14, 1192-6 | 4.5 | 36 |
| 21 | Crohn's disease: a review of current treatment with a focus on biologics. <i>Drugs</i> , 2007 , 67, 2511-37 | 12.1 | 53 |

| | | | |
|----|---|------|----|
| 20 | MDR1 polymorphisms and response to azathioprine therapy in patients with Crohn's disease. <i>Inflammatory Bowel Diseases</i> , 2007 , 13, 585-90 | 4.5 | 24 |
| 19 | Role of the PXR gene locus in inflammatory bowel diseases. <i>Inflammatory Bowel Diseases</i> , 2007 , 13, 1484-5 | 4.5 | 46 |
| 18 | CD209 in inflammatory bowel disease: a case-control study in the Spanish population. <i>BMC Medical Genetics</i> , 2007 , 8, 75 | 2.1 | 11 |
| 17 | Epistatic interaction between FCRL3 and MHC in Spanish patients with IBD. <i>Tissue Antigens</i> , 2007 , 69, 313-7 | | 11 |
| 16 | Influence of the inducible nitric oxide synthase gene (NOS2A) on inflammatory bowel disease susceptibility. <i>Immunogenetics</i> , 2007 , 59, 833-7 | 3.2 | 42 |
| 15 | GSTT1 and GSTM1 null genotypes may facilitate hepatitis C virus infection becoming chronic. <i>Journal of Infectious Diseases</i> , 2007 , 195, 1320-3 | 7 | 18 |
| 14 | MYO9B polymorphisms in patients with inflammatory bowel disease. <i>Gut</i> , 2007 , 56, 1321-2 | 19.2 | 26 |
| 13 | Association of the organic cation transporter OCTN genes with Crohn's disease in the Spanish population. <i>European Journal of Human Genetics</i> , 2006 , 14, 222-6 | 5.3 | 31 |
| 12 | MDR1 gene: susceptibility in Spanish Crohn's disease and ulcerative colitis patients. <i>Inflammatory Bowel Diseases</i> , 2006 , 12, 33-7 | 4.5 | 47 |
| 11 | Polymorphisms in interleukin-10 gene according to mutations of NOD2/CARD15 gene and relation to phenotype in Spanish patients with Crohn's disease. <i>World Journal of Gastroenterology</i> , 2006 , 12, 443-8 | 5.6 | 4 |
| 10 | Severity of ulcerative colitis is associated with a polymorphism at diamine oxidase gene but not at histamine N-methyltransferase gene. <i>World Journal of Gastroenterology</i> , 2006 , 12, 615-20 | 5.6 | 31 |
| 9 | Polymorphisms in the interleukin-10 gene and relation to phenotype in patients with ulcerative colitis. <i>Revista Espanola De Enfermedades Digestivas</i> , 2006 , 98, 93-100 | 0.9 | 1 |
| 8 | A computer-assisted morphometric quantitative analysis of iron overload in liver biopsies. A comparison with histological and biochemical methods. <i>Pathology Research and Practice</i> , 2005 , 201, 673-7 | 3.4 | 13 |
| 7 | A recombined haplotype in the major histocompatibility region contains a cluster of genes conferring high susceptibility to ulcerative colitis in the Spanish population. <i>Inflammatory Bowel Diseases</i> , 2005 , 11, 785-91 | 4.5 | 6 |
| 6 | IBD5 polymorphisms in inflammatory bowel disease: association with response to infliximab. <i>World Journal of Gastroenterology</i> , 2005 , 11, 1187-92 | 5.6 | 58 |
| 5 | Genetic predisposition to acute gastrointestinal bleeding after NSAIDs use. <i>British Journal of Pharmacology</i> , 2004 , 141, 205-8 | 8.6 | 93 |
| 4 | Impact of the recommendations made by Spanish Club for the Study of Helicobacter pylori on eradication indications. <i>Revista Espanola De Enfermedades Digestivas</i> , 2002 , 94, 332-9 | 0.9 | 0 |
| 3 | Topical anesthesia and urease tests. <i>Gastrointestinal Endoscopy</i> , 1996 , 44, 760 | 5.2 | |

| | | | |
|---|--|-----|----|
| 2 | Simultaneous two-level esophageal 24-hour pH monitoring in patients with mild and severe esophagitis. Does probe position influence results of esophageal monitoring?. <i>Digestive Diseases and Sciences</i> , 1995 , 40, 1423-7 | 4 | 5 |
| 1 | Comparison of sucralfate and ranitidine in the treatment of duodenal ulcers. <i>American Journal of Medicine</i> , 1991 , 91, 64S-67S | 2.4 | 10 |